Search
Toggle theme
Menu
Back
Home
Publications
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
Public
More options
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
N
Shared by
NobleBlocks
on Apr 1, 2025 • 12:00 AM UTC
Authors:
Stephan Weidinger
,
Andrew Blauvelt
,
Kim A. Papp
+17 more
Download PDF
Share
Summary
Sum
PDF
Figures
Figs
Discrepancies
Disc
EDDII
Article
Art
Finding related papers...
Discussions
(0)
Add Comment
No comments yet
Be the first to share your thoughts!
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis | NobleBlocks
